Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02—A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC

作者：Pasi A. Jänne, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang‐We Kim, David Planchard, Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, Elvire Pons‐Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong‐Wan Kim, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, K. Dunton, Ahmed Ali, Kōichi Goto · 发表于：Journal of Thoracic Oncology · 年份：2025 · DOI：10.1016/j.jtho.2025.07.129 · 被引用次数：21 · 研究领域：HER2/EGFR in Cancer Research、Lung Cancer Treatments and Mutations、Advanced Breast Cancer Therapies